Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Ocular Therapeutix Inc ( NASDAQ:OCUL ) has reached a key enrollment milestone in their SO1 trial, which is expected to accelerate enrollment in the SOLAR trial. The company has seen strong demand for participation in their clinical studies, indicating high interest from both patients and physicians. OCUL's financial position is strong, with approximately $427 million in cash and cash equivalents, providing a runway into 2028. The company has a remarkable commercial team achieving excellent results with Dextenza, which strengthens their market presence. OCUL's trials have shown promising results, with no vision-threatening complications observed in certain patient groups, highlighting the potential efficacy of their treatments. There is uncertainty regarding the regulatory submission process, as both SO1 and SOLAR studies need to be completed for approval. The company is s
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business HighlightsGlobeNewswire
- Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIVGlobeNewswire
- Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business OfficerGlobeNewswire
OCUL
Earnings
- 11/14/24 - Beat
OCUL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- OCUL's page on the SEC website